1. Home
  2. KMT vs RCUS Comparison

KMT vs RCUS Comparison

Compare KMT & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kennametal Inc.

KMT

Kennametal Inc.

BUY

Current Price

$38.78

Market Cap

2.9B

Sector

Industrials

ML Signal

BUY

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$22.36

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMT
RCUS
Founded
1938
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.8B
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
KMT
RCUS
Price
$38.78
$22.36
Analyst Decision
Hold
Buy
Analyst Count
6
11
Target Price
$36.00
$30.27
AVG Volume (30 Days)
1.0M
856.5K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
2.06%
N/A
EPS Growth
N/A
N/A
EPS
0.74
N/A
Revenue
$1,966,845,000.00
$247,000,000.00
Revenue This Year
$13.94
N/A
Revenue Next Year
$7.27
$83.23
P/E Ratio
$52.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.62
$7.06
52 Week High
$42.03
$26.40

Technical Indicators

Market Signals
Indicator
KMT
RCUS
Relative Strength Index (RSI) 57.75 51.85
Support Level $37.93 $20.18
Resistance Level $41.89 $24.33
Average True Range (ATR) 1.23 1.09
MACD 0.37 0.11
Stochastic Oscillator 85.17 66.52

Price Performance

Historical Comparison
KMT
RCUS

About KMT Kennametal Inc.

Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: